All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
17 results for "Cancer" and "Eye/Orbital Cancers"
A Phase 1b/2 Study of FT-2102 in Patients with Advanced Solid Tumors and Gliomas with an IDH1 Mutation
A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
Protocol No
FORMA-2102-ONC-102
Sub Category
Brain and Spine Cancers
Early Phase/Multiple Disease Site Cancers
Sarcoma
Gastrointestinal Cancers
An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Protocol No
GENENTECH-MYPATHWAY
Sub Category
Breast Cancers
Early Phase/Multiple Disease Site Cancers
Thoracic Cancers
Sarcoma
Skin Cancers
Prostate and Urologic Cancers
Head and Neck Cancers
Gynecologic Cancers
Gastrointestinal Cancers
Endocrine Cancers
A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Protocol No
TORAY-950P1V02
Sub Category
Breast Cancers
Early Phase/Multiple Disease Site Cancers
Thoracic Cancers
Sarcoma
Skin Cancers
Prostate and Urologic Cancers
Head and Neck Cancers
Gynecologic Cancers
Gastrointestinal Cancers
Molecular Analysis for Therapy Choice (MATCH)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Protocol No
ECOG-EAY131-MATCH
Sub Category
Hematologic/Blood Related Cancers
Early Phase/Multiple Disease Site Cancers
Thoracic Cancers
Sarcoma
Skin Cancers
Prostate and Urologic Cancers
Head and Neck Cancers
Gynecologic Cancers
Gastrointestinal Cancers
Eye/Orbital Cancers
Endocrine Cancers
Breast Cancers
Brain and Spine Cancers
A Phase 2, Single-Arm Study of Abemaciclib for Treatment of Advanced Soft Tissue and Bone Sarcoma Identified as having CDK Pathway Alteration
Abemaciclib for Treatment of Advanced Bone and Soft Tissue Sarcoma Identified as Having CDK Pathway Alteration
Protocol No
IIT-CHARLSON-BOAST
Sub Category
Sarcoma
A Phase 3, Interventional, Randomized, Multicenter, Open-label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib
DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib
Protocol No
DECIPHERA-DCC-2618-03-002
Sub Category
Gastrointestinal Cancers
Sarcoma
Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
Protocol No
ALLIANCE-N0577-CODEL
Sub Category
Brain and Spine Cancers
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adults Patients With Progressing Desmoid Tumors (DTs) Aggressive Fibromatosis (AF)
Nirogacestat Versus Placebo in Adult Patients with Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Protocol No
SPRINGWORKS-NIR-DT-301
Sub Category
Sarcoma
Study Evaluating Hypofractionated Pre-operative Radiation Therapy for Soft Tissue Sarcomas of the Extremity and Chest-Wall
Hypofractionated Pre-operative Radiation Therapy for Soft Tissue Sarcomas of the Extremity and Chest-wall
Protocol No
IIT-BEDI-HYPOFRACTIONATED
Sub Category
Sarcoma
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer
The purpose of this study is to compare any good and bad effects of avoiding the hippocampus during whole-brain radiation to the usual whole-brain radiation. The hippocampus is part of the brain that is important for memory. Avoiding the hippocampus during whole-brain radiation could decrease the chance of side effects on memory and thinking. It also is possible that avoiding the hippocampus could have no benefit or could cause other side effects. Hippocampal avoidance also could lessen the effectiveness of whole-brain radiation. This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach. To be better, the addition of the hippocampal avoidance technique to whole-brain radiation therapy should decrease the chance of side effects on memory or thinking by at least 14.5%.
Protocol No
NRG-CC003
Sub Category
Brain and Spine Cancers
Thoracic Cancers
An Open Label, Phase I Dose-finding Study of BI 754111 in Combination with BI 754091 in Patients with Advanced Solid Cancers Followed by Expansion Cohorts at the Selected Dose of the Combination in Patients with Non-small Cell Lung Cancer and Other Solid Tumors
This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.
Protocol No
BI-1381-REFMAL485
Sub Category
Breast Cancers
Early Phase/Multiple Disease Site Cancers
Thoracic Cancers
Sarcoma
Skin Cancers
Prostate and Urologic Cancers
Head and Neck Cancers
Gynecologic Cancers
Gastrointestinal Cancers
A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily for 14 Days to Patients with Advanced Solid Tumors
Phase I, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors
Protocol No
TOLERO-TP-1287-101
Sub Category
Breast Cancers
Early Phase/Multiple Disease Site Cancers
Thoracic Cancers
Sarcoma
Skin Cancers
Prostate and Urologic Cancers
Head and Neck Cancers
Gynecologic Cancers
Gastrointestinal Cancers
Endocrine Cancers
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
BLU-285 vs Regorafenib in GIST patient
Protocol No
BLUEPRINT-BLU-285-1303
Sub Category
Gastrointestinal Cancers
Sarcoma
Phase 2 Solid Tumor Immunotherapy Trial Using HLA-Haploidentical Transplant and Donor NK Cells: The STIR Trial
The purpose of this study is to evaluate the safety and efficacy of performing an allogeneic
transplant followed by NK cell infusion in patients with solid tumors. This study is also asking whether the addition of extra immune cells from the same haploidentical
donor one week after transplant is safe and can help treat your cancer. These cells are known as
natural killer cells or NK cells. The addition of NK cells is considered part of the investigational
therapy.
The experimental part of this treatment protocol is receiving the allogeneic HPCT and donor
NK cells.
transplant followed by NK cell infusion in patients with solid tumors. This study is also asking whether the addition of extra immune cells from the same haploidentical
donor one week after transplant is safe and can help treat your cancer. These cells are known as
natural killer cells or NK cells. The addition of NK cells is considered part of the investigational
therapy.
The experimental part of this treatment protocol is receiving the allogeneic HPCT and donor
NK cells.
Protocol No
IIT-THAKAR-STIR
Sub Category
Sarcoma
Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
Protocol No
NRG-BN003
Sub Category
Brain and Spine Cancers